HaffnerSM, LehtoS, RönnemaaT, PyöräläK, LaaksoM. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339:229–234.
2.
CollinsR, ArmitageJ, ParishS, SleighP Peto R; Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet, 2003; 14;361:2005–2016.
3.
ShepherdJ, BarterP, CarmenaR, DeedwaniaP, FruchartJC, HaffnerS, HsiaJ, BreaznaA, LaRosaJ, GrundyS, WatersD. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care, 2006; 29:1220–1226.
4.
ColhounHM, BetteridgeDJ, DurringtonPN, HitmanGA, NeilHA, LivingstoneSJ, ThomasonMJ, MacknessMI, Charlton-MenysV Fuller JH; CARDS investigators.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet, 2004; 364:685–696.
5.
National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106:3143–3121.
6.
ACCORD StudyGroup, GinsbergHN, ElamMB, LovatoLC, CrouseJR3rd, LeiterLA, LinzP, FriedewaldWT, BuseJB, GersteinHC, ProbstfieldJ, GrimmRH, Ismail-BeigiF, BiggerJT, GoffDCJr, CushmanWC, Simons-MortonDG, ByingtonRP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010; 29;362:1563–1574.
7.
GrundySM, VegaGL, YuanZ, BattistiWP, BradyWE, PalmisanoJ. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)Am J Cardiol, 2005; 15;95:462–468.
8.
GrundySM, VegaGL, TomassiniJE, TershakovecAM. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial)Am J Cardiol, 2009; 15;104:548–553.
9.
ScottR, O'BrienR, FulcherG, PardyC, D'EmdenM, TseD, TaskinenMR, EhnholmC, KeechA. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care, 2009; 32:493–498.
10.
Supplement to: The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010; 362:1563–1574(Appendix 1).
11.
GaedeP, VedelP, LarsenN, JensenGV, ParvingHH, PedersenO. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003; 30;348:383–393.
